Does Trazodone Increase Liver Enzymes?
Yes, trazodone can cause elevations in liver enzymes and hepatotoxicity, though this adverse effect is relatively uncommon. According to the FDA drug label, trazodone should be used with caution in patients with hepatic impairment, and appropriate monitoring is warranted 1.
Evidence from FDA Drug Labeling
The official FDA prescribing information does not provide specific incidence rates for hepatotoxicity, but acknowledges that trazodone is extensively metabolized by the liver (primarily via CYP3A4) and should be used cautiously in patients with hepatic dysfunction 1. The drug label specifically states that trazodone has not been formally studied in patients with hepatic impairment and recommends caution in this population 1.
Clinical Evidence of Hepatotoxicity
Multiple case reports and clinical studies document trazodone-associated liver injury:
A 2015 systematic review found that 0.5-3% of patients on antidepressants develop asymptomatic mild transaminase elevations, with lower risk for SSRIs compared to tricyclics 2. However, trazodone specifically has been linked to more severe hepatotoxicity in documented cases.
Case reports demonstrate hepatotoxicity can occur after variable durations of therapy—ranging from as short as 4 days to 18 months of treatment 3, 4. One case documented acute hepatitis and cholestasis after only 4 days of trazodone 200 mg/day 3, while another showed reversible liver injury after 18 months of use 4.
A 2013 review classified trazodone among antidepressants linked to causing death from hepatotoxicity, alongside nefazodone, duloxetine, bupropion, and sertraline 5. The review emphasized that onset varies from 5 days to 3 years, and most cases are reversible when detected early.
A 2009 case report documented fulminant hepatic failure requiring liver transplantation after 4 months of combined venlafaxine and trazodone therapy 6.
Mechanism and Metabolic Considerations
Recent research reveals that trazodone's hepatotoxicity may be mediated through its metabolite triazolopropionic aldehyde (M1), which can covalently bind to endogenous amines and interfere with glutathione biosynthesis 7. CYP2D6 poor metabolizers appear at higher risk for adverse drug reactions, including potential hepatotoxicity, due to accumulation of the active metabolite m-chlorophenylpiperazine (mCPP) 8, 9.
Clinical Monitoring Recommendations
Based on guideline evidence and case reports:
Baseline liver function tests (ALT, AST, alkaline phosphatase, total bilirubin) should be obtained before initiating trazodone, particularly in patients with risk factors for liver disease 10, 2.
Periodic monitoring during ongoing therapy is prudent, especially in the first 6 months when most cases manifest 2, 5. One guideline specifically recommends monitoring in patients on high-dose and prolonged therapy 11.
Immediately discontinue trazodone if clinically significant liver enzyme elevations occur or if signs/symptoms of liver dysfunction develop (jaundice, dark urine, right upper quadrant pain, unexplained fatigue) 5.
Important Caveats
The idiosyncratic nature of trazodone hepatotoxicity makes it unpredictable—it can occur in patients without pre-existing liver disease or identifiable risk factors 5, 4.
Patients with multiple risk factors for liver damage (hepatitis C, HIV, concurrent hepatotoxic medications) require closer monitoring 3.
Most documented cases show reversibility upon drug discontinuation, but rare cases of fulminant hepatic failure have occurred 6.
The 2023 frontotemporal dementia guideline noted that 42% of patients on trazodone 150-300 mg/day experienced side effects (fatigue, dizziness, hypotension), though hepatotoxicity was not specifically quantified 12.